Satellos Bioscience Inc. (MSLE) Stock Analysis & Investment Frameworks
Satellos Bioscience Inc. (MSLE) stock analysis on Invetso. Review Satellos Bioscience Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Satellos Bioscience Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
Satellos Bioscience Inc. Key Financial Metrics
- Market Cap: $8.32M
- Revenue: $N/A
- ROE: -72.67%
- ROIC: -60.09%
- Dividend Yield: N/A
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc. Investment Frameworks
Invetso analyzes Satellos Bioscience Inc. (MSLE) across the following frameworks:
- Satellos Bioscience Inc. 10Y Growth Potential
- Satellos Bioscience Inc. Scenario Analysis
- Satellos Bioscience Inc. Risks & Opportunities
- Satellos Bioscience Inc. Economic Moat
- Satellos Bioscience Inc. Business Model
- Satellos Bioscience Inc. Management
- Satellos Bioscience Inc. SWOT Analysis
- Satellos Bioscience Inc. Porter's 5 Forces
- Satellos Bioscience Inc. PESTLE Analysis
- Satellos Bioscience Inc. ESG Analysis